Preview Mode Links will not work in preview mode

Mar 1, 2019

Featuring interviews with Drs Sanjiv S Agarwala, Gary H Lyman and Hope S Rugo. | For more information, visit:


Interview with Hope Rugo, MD:

  • Overview of biosimilar agents: 0m0s
  • Regulatory pathway for the approval of biosimilars: 2m48s
  • Valid short-term endpoints in the clinical development of biosimilars: 6m23s
  • Extrapolating the use of biosimilars; potential combination of biosimilars with other agents: 8m42s
  • Design of the Phase III HERITAGE study evaluating the trastuzumab biosimilar MYL-1401O versus trastuzumab for HER2-positive metastatic breast cancer: 11m1s
  • Efficacy and safety of trastuzumab biosimilars: 13m43s
  • Biosimilars currently approved for cancer in the United States: 16m26s
  • Clinical implications of the HERITAGE trial for patients with HER2-positive metastatic breast cancer: 18m33s
  • Activity and use of filgrastim biosimilars in clinical practice: 19m48s
  • Emerging data with rituximab biosimilars: 21m59s
  • Common myths among oncologists regarding biosimilars: 22m59s
  • Availability of biosimilar agents in the United States and ongoing monitoring for safety: 24m31s